These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 24332514

  • 1. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
    Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, Timmins H, Wheatley D, Grieve R, Griffiths G, Murray N.
    Lancet Oncol; 2014 Jan; 15(1):114-22. PubMed ID: 24332514
    [Abstract] [Full Text] [Related]

  • 2. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K, Plosker GL.
    Pharmacoeconomics; 2008 Jan; 26(3):251-68. PubMed ID: 18282018
    [Abstract] [Full Text] [Related]

  • 3. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates.
    Nelson A, Fenlon D, Morris J, Sampson C, Harrop E, Murray N, Wheatley D, Hood K, Griffiths G, Barrett-Lee P.
    Trials; 2013 Oct 09; 14():325. PubMed ID: 24107437
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.
    Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI.
    Lancet Oncol; 2013 Jun 09; 14(7):663-70. PubMed ID: 23684411
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
    Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA, National Cancer Research Institute Haematological Oncology Clinical Study Group.
    Lancet; 2010 Dec 11; 376(9757):1989-99. PubMed ID: 21131037
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
    Raje N, Terpos E, Willenbacher W, Shimizu K, García-Sanz R, Durie B, Legieć W, Krejčí M, Laribi K, Zhu L, Cheng P, Warner D, Roodman GD.
    Lancet Oncol; 2018 Mar 11; 19(3):370-381. PubMed ID: 29429912
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN, HORIZON investigators.
    Lancet; 2009 Apr 11; 373(9671):1253-63. PubMed ID: 19362675
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.
    Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Wu P, Davies FE, National Cancer Research Institute Haematological Oncology Clinical Studies Group.
    Lancet Oncol; 2011 Aug 11; 12(8):743-52. PubMed ID: 21771568
    [Abstract] [Full Text] [Related]

  • 18. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.
    Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D.
    Br J Cancer; 2005 May 23; 92(10):1869-76. PubMed ID: 15870721
    [Abstract] [Full Text] [Related]

  • 19. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C.
    Clin Drug Investig; 2013 Feb 23; 33(2):117-22. PubMed ID: 23184667
    [Abstract] [Full Text] [Related]

  • 20. Bisphosphonates for breast cancer.
    Pavlakis N, Schmidt R, Stockler M.
    Cochrane Database Syst Rev; 2005 Jul 20; (3):CD003474. PubMed ID: 16034900
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.